fitforthem
about

scope and guide to the platform

—research groups

research groups network graph visualization

—repositories

catalog of the institutional repositories

—heritage

selection of collections, museum, cultural sites and ancient books

By continuing your visit to this site, you accept the use of essential cookies.

Read more
6533b826fe1ef96bd128491d

RESEARCH PRODUCT

Enzyme replacement therapy in Fabry disease: Comparison of agalsidase alfa and agalsidase beta

Gregory M. PastoresMichael BeckChristoph KampmannGere Sunder-plassmannDominique P. GermainAtul MehtaAndrea Frustaci

subject

medicine.medical_specialtybusiness.industryEndocrinology Diabetes and MetabolismUrologyEnzyme replacement therapymedicine.diseaseBiochemistryFabry diseaseAGALSIDASE BETAEndocrinologyGeneticsmedicinebusinessMolecular BiologyAgalsidase alfa
yearjournalcountryeditionlanguage
2008-09-01Molecular Genetics and Metabolism
https://doi.org/10.1016/j.ymgme.2008.07.002
EU flag

FORTHEM European University Alliance is co-funded by the European Union. FIT FORTHEM has received funding from the European Union's Horizon 2020 Research and Innovation Programme under grant agreement No. 101017248. The content of this website represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission.

University of Jyväskylä logoUniversity of Jyväskylä's websiteUniversity of Burgundy logoUniversity of Burgundy's websiteUniversity of Mainz logoUniversity of Mainz's websiteUniversity of Palermo logoUniversity of Palermo's websiteUniversity of Latvia logoUniversity of Latvia's website
University of Agder logoUniversity of Agder's websiteUniversity of Opole logoUniversity of Opole's websiteUniversity of Sibiu logoUniversity of Sibiu's websiteUniversity of València logoUniversity of València's website
FORTHEM logoFORTHEM alliance's website